Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Black Diamond Therapeutics, Inc.
High uncertainty: The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-46.5% vs price
Base Case (Median)
-45.5% vs price
Bull Case (75th pct.)
27.0% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $1.05 | -47.6% | High (40%) |
| EV/EBITDA | $3.99 | 99.7% | Medium (20%) |
| Earnings Power Value | $1.09 | -45.5% | Medium (50%) |
Based on 3 out of 7 methods, BDTX appears fairly valued at the current price of $2.00. The base case fair value of $1.09 implies 45.5% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.